Third Pole Therapeutics

Third Pole Therapeutics is pioneering a tankless, portable platform for generating inhaled nitric oxide (iNO), a critical therapy for pulmonary hypertension and other respiratory conditions. The company's lead investigational device, eNOfit, is designed as a wearable system, representing a significant departure from the current standard of large, stationary gas cylinders. With foundational technology from Harvard/MGH and recent successful feasibility studies, Third Pole is advancing toward clinical trials and potential commercialization. The company is privately held, backed by strategic equity investments, and targets a substantial market opportunity in both hospital and ambulatory settings.

Proprietary electrochemical platform that generates pure nitric oxide (NO) on-demand from ambient air for inhalation therapy, enabling portable and tankless delivery systems.

Third Pole's primary competition is the established standard of care: cylinder-based iNO delivery systems from large players like Mallinckrodt (which markets INOmax). Its key differentiator is the elimination of gas cylinders. Potential future competitors include other companies developing alternative portable NO generation technologies or novel pulmonary vasodilators.